Trump Admin Delays Next Steps For Int’l Pricing Index, Rebate Rule

By Rachel Cohrs / May 22, 2019 at 11:19 AM
The Trump administration’s spring regulatory agenda , released Wednesday (May 22), shows that two of HHS’ most disruptive drug-pricing regulatory actions -- its proposal to base Medicare Part B pay rates on foreign drug prices and its overhaul of the rebate system -- are set to be released later than originally anticipated. November is the new estimated release window for CMS’ final rule to require that rebates be passed through to consumers in Medicare Part D and Medicaid managed...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.